Form 8-K - Current report:
SEC Accession No. 0000950170-24-123703
Filing Date
2024-11-08
Accepted
2024-11-08 08:00:08
Documents
12
Period of Report
2024-11-07
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aktx-20241107.htm   iXBRL 8-K 80638
2 EX-99.1 aktx-ex99_1.htm EX-99.1 24901
  Complete submission text file 0000950170-24-123703.txt   333184

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT aktx-20241107.xsd EX-101.SCH 92829
14 EXTRACTED XBRL INSTANCE DOCUMENT aktx-20241107_htm.xml XML 6094
Mailing Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210
Business Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210 (646) 350-0702
Akari Therapeutics Plc (Filer) CIK: 0001541157 (see all company filings)

EIN.: 981034922 | State of Incorp.: X0
Type: 8-K | Act: 34 | File No.: 001-36288 | Film No.: 241438044
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)